Comparison of serious adverse events between the original and a generic docetaxel in breast cancer patients.
about
Toxicity Assessment of a Phase III Study Evaluating FEC-Doc and FEC-Doc Combined with Gemcitabine as an Adjuvant Treatment for High-Risk Early Breast Cancer: the SUCCESS-A Trial.Toxicities of docetaxel: original drug versus generics-a comparative study about 81 casesComparing the Incidence of Febrile Neutropenia Resulting in Hospital Admission Between the Branded Docetaxel and the Generic Formulations.
P2860
Comparison of serious adverse events between the original and a generic docetaxel in breast cancer patients.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年学术文章
@wuu
2013年学术文章
@zh
2013年学术文章
@zh-cn
2013年学术文章
@zh-hans
2013年学术文章
@zh-my
2013年学术文章
@zh-sg
2013年學術文章
@yue
2013年學術文章
@zh-hant
name
Comparison of serious adverse ...... xel in breast cancer patients.
@en
Comparison of serious adverse ...... xel in breast cancer patients.
@nl
type
label
Comparison of serious adverse ...... xel in breast cancer patients.
@en
Comparison of serious adverse ...... xel in breast cancer patients.
@nl
prefLabel
Comparison of serious adverse ...... xel in breast cancer patients.
@en
Comparison of serious adverse ...... xel in breast cancer patients.
@nl
P2093
P2860
P356
P1476
Comparison of serious adverse ...... xel in breast cancer patients.
@en
P2093
Anne-France Leblond
Brigitte Poirier
Catherine Doyle
Christine Desbiens
Eric Poirier
Guy Cantin
Isabelle Côté
Jean-Charles Hogue
Julie Lemieux
Louise Provencher
P2860
P304
P356
10.1177/1060028013514941
P407
P577
2013-12-09T00:00:00Z